Eurobio Scientific SA
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and oncology. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, for heart transplant monito… Read more
Eurobio Scientific SA (ALERS) - Total Assets
Latest total assets as of June 2025: €259.11 Million EUR
Based on the latest financial reports, Eurobio Scientific SA (ALERS) holds total assets worth €259.11 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eurobio Scientific SA - Total Assets Trend (2007–2024)
This chart illustrates how Eurobio Scientific SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eurobio Scientific SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Eurobio Scientific SA's total assets of €259.11 Million consist of 34.8% current assets and 65.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €23.07 Million | 8.5% |
| Accounts Receivable | €33.16 Million | 12.9% |
| Inventory | €26.92 Million | 10.5% |
| Property, Plant & Equipment | €12.77 Million | 5.0% |
| Intangible Assets | €34.62 Million | 13.5% |
| Goodwill | €118.90 Million | 46.2% |
Asset Composition Trend (2007–2024)
This chart illustrates how Eurobio Scientific SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eurobio Scientific SA's current assets represent 34.8% of total assets in 2024, a decrease from 90.2% in 2007.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2024, down from 17.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 5.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 46.2% of total assets.
Eurobio Scientific SA Competitors by Total Assets
Key competitors of Eurobio Scientific SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Eurobio Scientific SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Eurobio Scientific SA generates 0.60x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Eurobio Scientific SA generates $ 1.56 in net profit.
Eurobio Scientific SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.68 | 2.69 | 1.87 |
| Quick Ratio | 1.86 | 2.26 | 1.55 |
| Cash Ratio | 0.74 | 1.59 | 0.42 |
| Working Capital | €60.76 Million | € 92.12 Million | € 33.99 Million |
Eurobio Scientific SA - Advanced Valuation Insights
This section examines the relationship between Eurobio Scientific SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -18.7% |
| Total Assets | €257.17 Million |
| Market Capitalization | $5.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Eurobio Scientific SA's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Eurobio Scientific SA's assets decreased by 18.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eurobio Scientific SA (2007–2024)
The table below shows the annual total assets of Eurobio Scientific SA from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €257.17 Million | -18.70% |
| 2023-12-31 | €316.33 Million | -4.26% |
| 2022-12-31 | €330.42 Million | +57.92% |
| 2021-12-31 | €209.22 Million | +21.43% |
| 2020-12-31 | €172.30 Million | +112.70% |
| 2019-12-31 | €81.01 Million | +15.89% |
| 2018-12-31 | €69.90 Million | -2.34% |
| 2017-12-31 | €71.57 Million | +124.46% |
| 2016-12-31 | €31.89 Million | -10.71% |
| 2015-12-31 | €35.71 Million | -11.81% |
| 2014-12-31 | €40.50 Million | +21.20% |
| 2013-12-31 | €33.41 Million | -13.20% |
| 2012-12-31 | €38.49 Million | +118.68% |
| 2011-12-31 | €17.60 Million | -43.69% |
| 2010-12-31 | €31.26 Million | -14.47% |
| 2009-12-31 | €36.55 Million | +22.45% |
| 2008-12-31 | €29.85 Million | -20.60% |
| 2007-12-31 | €37.59 Million | -- |